Therefore, results summarized in the following sections report key pharmacodynamic and lipid data (ANGPTL3, TG, non-HDL-C, VLDL-C, LDL-C, HDL-C and ApoB concentrations) 12 weeks after the last dose, corresponding to day 85 for single dose (HP SAD cohorts) and day 113 for multiple doses (HP MAD and hepatic steatosis cohorts). The gene discussed is APOB; the disease is Hepatic steatosis.